LONDON, UK / ACCESSWIRE / May 4, 2018 / If you want access to our free earnings report on Chemed Corp. (NYSE: CHE) all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CHE. On April 19, 2018, Chemed reported financial results for the first quarter of 2018 ending March 31, 2018. The Company surpassed analysts' estimates for earnings as well as revenue in Q1 FY18. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Chemed most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=CHE

Earnings Highlights and Summary

Chemed had total service revenues and sales of $439.18 million in Q1 FY18, an increase of 8.21% from $405.86 million in Q1 FY17. The reported revenue number exceeded analysts' consensus estimates of $420 million.

Chemed's total costs and expenses in the quarter ending March 31, 2018, were $382.78 million, 5.04% higher than the $364.41 million reported in the same period in the previous year. In the quarter under review, the Company's cost of goods and services advanced 6.80% to $304.54 million on a y-o-y basis while selling, general, and administrative (SG&A) expenses declined 0.66% to $69 million on a y-o-y basis. Chemed's income from operations jumped 36.05% to $56.40 million in Q1 FY18 from $41.45 million in Q1 FY17. The Company's adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) also increased 21.65% to $72.77 million in the quarter under review from $59.82 million in the year-ago same quarter.

Chemed reported a net income of $45 million in Q1 FY18, reflecting an increase of 50.77% from $29.84 million in Q1 FY17. The Company's diluted earnings per share (DEPS) also rose 49.44% to $2.66 in the reported quarter from $1.78 in the year-ago comparable quarter. The reported earnings included excess tax benefits on stock compensation, stock option expense, long-term incentive compensation, and Medicare cap sequestration adjustment. Excluding these non-recurring items, Cheme's adjusted DEPS was $2.72 in Q1 FY18, up 49.45% from $1.82 in Q1 FY17. This was higher than analysts' consensus estimates of $2.37 per share.

Chemed's Segment Details

During Q1 FY18, the VITAS Healthcare segment's total service revenues and sales were $292.01 million, up 3.43% y-o-y. This segment had an adjusted EBITDA of $44.69 million in Q1 FY18, an increase of 16.31% from $38.42 million in Q1 FY17. VITAS segment's net income also hiked 55.44% to $32.02 million on a y-o-y basis in the reported quarter.

The Roto-Rooter segment had service revenues and sales of $147.16 million in Q1 FY18, an increment of 19.11% from the prior year's same quarter. This segment's adjusted EBITDA advanced 28.66% to $33.88 million in Q1 FY18 from $26.34 million in Q1 FY17. Roto-Rooter segment's net income also increased 56.85% to $22.94 million on a y-o-y basis in the quarter under review.

Cash Matters

Chemed had cash and cash equivalents of $13.69 million as on March 31, 2018, compared to $47.05 million as on March 31, 2017. The Company's net cash flow from operating activities was $65.19 million in Q1 FY18, a decrease of 5.22% from $68.79 million in Q1 FY17. The Company incurred capital expenditures of $12.65 million in the reported quarter, 40.22% higher than the $9.02 million reported in the year-ago corresponding quarter.

Chemed had a long-term debt of $132.50 million at the end of Q1 FY18, 3.64% lower than the $137.50 million reported at the end of Q1 FY17. As on March 31, 2018, the Company had undrawn borrowing capacity of approximately $244 million under its five-year Amended and Restated Credit Agreement.

On March 06, 2018, Chemed's Board of Directors authorized an additional $150 million for stock repurchase under Chemed's existing share repurchase program. As of March 31, 2018, the Company had a remaining share repurchase authorization of $124.40 million under this plan. In the quarter under review, Chemed repurchased 300,000 shares of common stock for $81.10 million and distributed dividends of $4.53 million.

Outlook

Chemed reiterated its earnings guidance issued in February 2018. The Company expects its full-year 2018 adjusted DEPS, excluding non-cash expense for stock options, costs related to litigation, and other discrete items, to be in the range of $10.60 to $10.85.

Chemed's Q1 FY18 exceeded expectations, hence the Company anticipates providing an updated guidance for the second half of 2018 when it reports its Q2 FY18 results.

Stock Performance Snapshot

May 3, 2018 - At Thursday's closing bell, Chemed's stock slightly rose 0.18%, ending the trading session at $312.38.

Volume traded for the day: 106.67 thousand shares.

Stock performance in the last month ? up 12.29%; previous three-month period ? up 17.74%; past twelve-month period ? up 53.13%; and year-to-date ? up 28.54%

After yesterday's close, Chemed's market cap was at $4.92 billion.

Price to Earnings (P/E) ratio was at 50.30.

The stock has a dividend yield of 0.36%.

The stock is part of the Healthcare sector, categorized under the Home Health Care industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors